Molecular Partners AG
Company founded: November 2004
Targeted Protein Therapeutics Beyond Antibodies.
Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches.
Milestones / News
|
17.01.2013 Molecular Partners publishes encouraging results of a clinical study |
Contact
Sharing
| Share this profile with others |




